Prescient TherapeuticsASX:PTX -7.58% Quick Ratio is 12.96 as of Dec. 2025, which is 18% below its 10-year median of 15.81. The stock has 2 warning signs investors should review. Among 1,413 Biotechnology companies, Prescient Therapeutics ranks better than 83.79% on this metric.
Prescient Therapeutics has a quick ratio of 12.96. It generally indicates good short-term financial strength.
The historical rank and industry rank for Prescient Therapeutics's Quick Ratio or its related term are showing as below:
ASX:PTX'
s Quick Ratio Range Over the Past 10 Years
Min: 4.08 Med: 15.81 Max: 80.24
Current: 12.96
During the past 13 years, Prescient Therapeutics's highest Quick Ratio was 80.24. The lowest was 4.08. And the median was 15.81.
ASX:PTX's Quick Ratio is ranked better than 83.79% of 1413
companies
in the Biotechnology industry
Industry Median: 3.6
vs ASX:PTX: 12.96
Prescient Therapeutics (ASX:PTX) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Prescient Therapeutics Quick Ratio Related Terms
Prescient Therapeutics Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:PTX vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Prescient Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prescient Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Prescient Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Prescient Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Prescient Therapeutics's Quick Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prescient Therapeutics (ASX:PTX) has a Quick Ratio of 12.96 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Prescient Therapeutics and its competitors. This is 18% below median its historical median of 15.81. Over the past decade, Prescient Therapeutics' Quick Ratio has ranged from 4.08 to 80.24. According to the industry distribution chart, Prescient Therapeutics ranks #229 out of 1413 companies in the Biotechnology industry, placing it in the top 16.2%.
Is Prescient Therapeutics' Quick Ratio too high?
Prescient Therapeutics' current Quick Ratio of 12.96 is 18% below median its 10-year median of 15.81. Over the past 10 years, this metric has ranged from a low of 4.08 to a high of 80.24. The Biotechnology industry median Quick Ratio is 3.60. Prescient Therapeutics' value of 12.96 is 260% above this industry median. Based on the distribution chart, Prescient Therapeutics ranks #229 out of 1413 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Prescient Therapeutics' Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Prescient Therapeutics ranks #229 out of 1413 companies for Quick Ratio. This places Prescient Therapeutics in the top 16% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Prescient Therapeutics' value of 12.96 is 260% above this benchmark. Historically, Prescient Therapeutics' own Quick Ratio has ranged from 4.08 to 80.24 over the past decade. While the company's 10-year median is 15.81 vs. the industry median of 3.60, Prescient Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,413 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prescient Therapeutics's current Quick Ratio of 12.96 is 260% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Prescient Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prescient Therapeutics's current Quick Ratio is 12.96, which is 18% below median its own 10-year median of 15.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prescient Therapeutics stock overvalued right now?
Prescient Therapeutics (ASX:PTX) has a current Quick Ratio of 12.96. The current Quick Ratio is 12.96, which is 18% below median its 10-year median of 15.81 and 260% above the Biotechnology industry median of 3.60. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Prescient Therapeutics (ASX:PTX), the current Quick Ratio is 12.96 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PTX has been successfully added to your 